Profile data is unavailable for this security.
About the company
Biotage AB is a Sweden-based company that develops and sells systems, consumables and services in the field of life sciences. Its customers include pharmaceutical and biotechnology companies, companies within the food industry and academic institutions. The Company offers systems and services within three areas: analytical chemistry, organic chemistry and industrial resins. Biotage’s offering within analytical chemistry consists of consumables with related applications to extract selected substances from various types of samples. The Company’s offering within organic chemistry includes products for pharmaceutical development based on both small molecules and peptides and its offering within industrial resins is composed of polymer-based resins and research services that lead to the development and manufacture of polymer-based materials. As of December 31, 2013, the Company operated 12 wholly owned subsidiaries worldwide.
- Revenue in SEK (TTM)2.13bn
- Net income in SEK257.00m
- Incorporated1997
- Employees675.00
- LocationBiotage ABVimpelgatan 5UPPSALA 753 18SwedenSWE
- Phone+46 18565900
- Fax+46 18591922
- Websitehttps://www.biotage.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medistim ASA | 546.54m | 101.54m | 2.58bn | 152.00 | 25.41 | 6.37 | 20.42 | 4.73 | 5.55 | 5.55 | 29.87 | 22.12 | 1.13 | 0.7461 | 7.48 | 3,599,204.00 | 21.05 | 22.93 | 25.53 | 28.52 | 79.12 | 78.25 | 18.58 | 20.64 | 2.75 | -- | 0.0181 | 75.25 | 7.00 | 10.06 | -8.91 | 12.72 | 0.033 | 14.87 |
| CellaVision AB | 737.16m | 150.21m | 5.12bn | 228.00 | 34.06 | 6.66 | 26.67 | 6.94 | 6.30 | 6.30 | 30.91 | 32.19 | 0.7849 | 1.91 | 7.26 | 3,233,162.00 | 15.99 | 15.30 | 18.45 | 18.24 | 66.99 | 69.03 | 20.38 | 19.98 | 2.15 | 1,358.86 | 0.044 | 110.18 | 5.94 | 13.17 | 10.12 | 8.00 | 30.45 | 8.45 |
| RaySearch Laboratories AB (publ) | 1.17bn | 175.06m | 5.31bn | 414.00 | 39.11 | 8.44 | 12.77 | 4.55 | 5.10 | 5.10 | 34.09 | 23.65 | 0.6023 | 5.51 | 3.29 | 3,005,152.00 | 9.02 | 1.29 | 13.69 | 1.88 | 91.06 | 90.57 | 14.97 | 2.55 | 1.27 | 108.61 | 0.3706 | 69.00 | 21.16 | 10.26 | 243.06 | 0.7648 | -1.31 | -- |
| Surgical Science Sweden AB | 859.83m | 193.34m | 7.45bn | 270.00 | 38.56 | 1.68 | 29.62 | 8.67 | 3.79 | 3.79 | 16.85 | 87.19 | 0.1769 | 1.56 | 6.80 | 3,307,035.00 | 3.98 | 4.49 | 4.21 | 4.78 | 68.65 | 70.06 | 22.49 | 23.75 | 3.73 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
| Arjo AB (publ) | 11.18bn | 511.00m | 8.35bn | 6.85k | 17.50 | 1.14 | 5.58 | 0.7464 | 1.88 | 1.88 | 41.05 | 28.87 | 0.7149 | 4.54 | 6.78 | 1,644,896.00 | 3.26 | 3.55 | 4.62 | 5.55 | 43.64 | 44.01 | 4.56 | 5.41 | 0.626 | 3.97 | 0.4073 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
| Revenio Group Oyj | 1.18bn | 220.23m | 8.59bn | 230.00 | 38.56 | 7.30 | 30.56 | 7.26 | 0.7204 | 0.7204 | 3.86 | 3.81 | 0.7834 | 4.93 | 8.17 | 472,574.10 | 14.67 | 14.33 | 17.09 | 17.90 | 49.29 | 50.73 | 18.72 | 21.13 | 1.51 | 34.57 | 0.1276 | 55.81 | -0.4125 | 25.80 | -12.15 | 18.72 | 17.67 | 6.30 |
| Biotage AB | 2.13bn | 257.00m | 12.10bn | 675.00 | 47.08 | 3.17 | 27.62 | 5.69 | 3.21 | 3.21 | 26.56 | 47.60 | 0.4312 | 1.59 | 7.22 | 3,155,786.00 | 5.21 | 10.74 | 6.05 | 12.77 | 62.67 | 61.40 | 12.08 | 15.75 | 1.15 | 43.88 | 0.0616 | 40.11 | 19.54 | 15.50 | -8.21 | 7.97 | 14.05 | 1.30 |
| ChemoMetec A/S | 633.56m | 211.70m | 12.22bn | 173.00 | 57.74 | 13.92 | 51.10 | 19.29 | 7.83 | 7.83 | 23.44 | 32.48 | 0.6112 | 0.745 | 6.97 | 2,357,630.00 | 20.42 | 27.96 | 24.40 | 35.10 | 78.80 | 79.57 | 33.41 | 35.02 | 3.76 | -- | 0.0073 | 144.08 | -8.22 | 18.37 | -23.72 | 26.64 | 9.97 | -11.81 |
| Xvivo Perfusion AB | 750.59m | 204.27m | 14.05bn | 161.00 | 67.79 | 6.74 | 50.90 | 18.72 | 6.58 | 6.58 | 24.07 | 66.13 | 0.3325 | 1.14 | 4.67 | 4,691,194.00 | 9.05 | 1.24 | 9.68 | 1.33 | 74.41 | 73.14 | 27.21 | 4.76 | 4.23 | -- | 0.0117 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
| AddLife AB | 10.01bn | 117.00m | 15.52bn | 2.36k | 137.17 | 3.13 | 14.79 | 1.55 | 0.9601 | 0.9601 | 82.16 | 42.09 | 0.7625 | 3.50 | 5.58 | 4,351,152.00 | 0.9063 | 5.31 | 1.29 | 8.83 | 37.30 | 36.89 | 1.19 | 5.79 | 0.638 | 1.66 | 0.5146 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| Elekta AB (publ) | 18.12bn | 1.13bn | 22.78bn | 4.57k | 20.86 | 2.21 | 9.87 | 1.26 | 2.96 | 2.96 | 47.38 | 28.01 | 0.5822 | 3.16 | 2.89 | 3,903,469.00 | 3.65 | 4.19 | 6.53 | 7.51 | 36.76 | 39.03 | 6.27 | 7.37 | 0.7425 | 3.91 | 0.4196 | 68.60 | 7.41 | 5.98 | 38.07 | 1.68 | 20.06 | 5.92 |
| Embla Medical hf | 9.29bn | 763.86m | 24.27bn | 4.00k | 31.98 | 2.80 | 17.76 | 2.61 | 1.14 | 1.14 | 13.87 | 13.06 | 0.5755 | 2.23 | 6.65 | 1,496,136.00 | 4.75 | 4.06 | 5.51 | 4.76 | 62.02 | 62.47 | 8.25 | 6.91 | 1.26 | 6.59 | 0.4074 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
| Vitrolife AB | 3.55bn | -3.81bn | 28.82bn | 1.10k | -- | 2.19 | -- | 8.11 | -28.10 | -28.10 | 26.24 | 97.03 | 0.1867 | 3.48 | 6.48 | 3,293,791.00 | -19.99 | -4.57 | -20.71 | -4.78 | 58.16 | 58.38 | -107.03 | -21.89 | 2.36 | 9.24 | 0.135 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
Data as of Nov 22 2024. Currency figures normalised to Biotage AB's reporting currency: Swedish Krona SEK
44.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Didner & Gerge Fonder ABas of 30 Jun 2024 | 6.37m | 7.95% |
| Carnegie Fonder ABas of 10 Oct 2024 | 6.37m | 7.95% |
| SEB Investment Management ABas of 31 Oct 2024 | 4.64m | 5.80% |
| Handelsbanken Fonder ABas of 31 Dec 2023 | 3.25m | 4.06% |
| Fj�rde AP-fondenas of 31 Dec 2023 | 2.77m | 3.46% |
| Invesco Advisers, Inc.as of 30 Sep 2024 | 2.65m | 3.32% |
| Swedbank Robur Fonder ABas of 31 Dec 2023 | 2.60m | 3.25% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 2.55m | 3.19% |
| F�rsta AP-fondenas of 31 Dec 2023 | 2.50m | 3.12% |
| Tredje AP-fondenas of 31 Dec 2023 | 2.25m | 2.81% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
